Allergan (NYSE:AGN) is one of the largest pharmaceutical powerhouses, operating in many areas including eye care, facial aesthetics, plastic surgery, skin care and neuroscience and urology. Allergan’s history is quite interesting as the company has grown via many big acquisitions.
Allergan, previously known as Actavis, has spent $8.5 billion to acquire Warner Chilcott plc. With this acquisition, Allergan set the strong foundation in several key areas including women’s health, urology, gastroenterology and dermatology. In 2014, the company acquired Forest Laboratories for $25 billion. Forest Laboratories was considered a good fit for Allergan due to its strong legacy in branded specialty and primary care pharmaceuticals. In the same year, Actavis and Allergan decided to merge with the total deal value of $66 billion, creating a new industry model called Growth Pharma, with world-class brand franchises, a global generics business and a premier pipeline of pharmaceutical development. Continue Reading »